4-[1-[5,6-dihydro-3,5,5-trimethyl-8-(1-methylethyl)-2-naphthalenyl]ethenyl]benzoic acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 4-[1-[5,6-dihydro-3,5,5-trimethyl-8-(1-methylethyl)-2-naphthalenyl]ethenyl]benzoic acid
• 英文别名: 4-[1-(3,5,5-trimethyl-8-propan-2-yl-6H-naphthalen-2-yl)ethenyl]benzoic acid
• 化学式: C₂₅H₂₈O₂
• 分子量: 360.496
• InChiKey: PARQIKCEABKMRR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.1
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  ethyl 4-[(3,5,5-trimethyl-5,6-dihydro-8-isopropyl-2-naphthalenyl)ethenyl]benzoate 在 盐酸 、 sodium hydroxide 作用下， 以86%的产率得到4-[1-[5,6-dihydro-3,5,5-trimethyl-8-(1-methylethyl)-2-naphthalenyl]ethenyl]benzoic acid
  参考文献：
  名称：

  Retinoic acid receptor antagonists as promoters of angiogenesis

  摘要：

  提供了通过单独或与其他治疗剂联合或结合使用维甲酸受体拮抗剂的治疗方法和组合物，以治疗各种疾病，促进血管生成。还提供了获取额外的维甲酸受体拮抗剂用作治疗剂以促进血管生成的方法。

  公开号：

  US20020120006A1

文献信息

• Method of inducing lung branching
  申请人：Institut National De La Sante Et De La Recherche Medicale

  公开号：US20020048580A1

  公开（公告）日：2002-04-25

  The invention relates to a method of treating lung branching malformation in a subject by administering to the subject a pharmaceutically effective amount of a retinoic acid receptor (RAR) retinoid. The invention also relates to a method of increasing alveoli in a subject by administering a pharmaceutically effective amount of a retinoic acid receptor (RAR) antagonist. The invention further relates to a method of inducing primary lung bud formation in a subject by administering a pharmaceutically effective amount of a retinoic acid receptor agonist. The invention also relates to a method of identifying an agent capable of inducing primary lung bud formation, the method comprising: (a) administering an agent to an embryo; and (b) determining primary lung bud formation of said embryo.

  本发明涉及一种通过向受试者施用药学有效量的维甲酸受体（RAR）维甲酸来治疗受试者肺分支畸形的方法。本发明还涉及一种通过施用药学有效量的维甲酸受体（RAR）拮抗剂来增加受试者肺泡的方法。本发明进一步涉及一种通过施用药学有效量的维甲酸受体激动剂诱导受试者原发性肺芽形成的方法。本发明还涉及一种鉴定能够诱导原发性肺芽形成的药剂的方法，该方法包括：(a) 对胚胎施用药剂；(b) 确定所述胚胎的原发性肺芽形成。
• Compositions and methods for use in modulating immune system function
  申请人：——

  公开号：US20020090352A1

  公开（公告）日：2002-07-11

  Vitamin A (retinol) deficiency results in impaired response to infection and increased mortality. By the present invention, we show that retinol activates immature dendritic cells (DC) and enhances antigen presentation via a cross-talk with inflammatory cytokines, whereas it increases DC death in the absence of these cytokines. These effects, that are mediated through retinoic acids and distinct nuclear retinoid receptor pathways, can be dissociated from each other with selective synthetic retinoids. The present invention identifies a novel cellular target and function for retinoids, provides compositions and methods for modulating the immune system and for treating or preventing various physical disorders in animals, preferably via controlling activation and/or apoptosis in antigen-presenting cells using selective retinoids.

  维生素 A（视黄醇）缺乏会导致对感染的反应减弱和死亡率升高。通过本发明，我们发现视黄醇能激活未成熟树突状细胞（DC），并通过与炎症细胞因子的交叉作用增强抗原递呈，而在没有这些细胞因子的情况下，视黄醇会增加 DC 的死亡。这些作用是通过视黄酸和不同的核视黄酸受体途径介导的，可以通过选择性合成视黄酸来相互分离。本发明确定了视黄酸的新细胞靶点和功能，提供了调节免疫系统和治疗或预防动物各种身体疾病的组合物和方法，最好是通过使用选择性视黄酸来控制抗原递呈细胞的活化和/或凋亡。
• COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES
  申请人：Bristol-Myers Squibb Company

  公开号：EP1173061A1

  公开（公告）日：2002-01-23
• Method for treating cachexia with retinoid ligands
  申请人：Jiang Guang Liang

  公开号：US20070185055A1

  公开（公告）日：2007-08-09

  The present invention relates to a method of treatment of cachexia in a subject in need of treatment. More specifically, the present invention relates to the use of retinoid compounds that act on retinoid X receptors (RXRs) for the treatment of cachexia in a subject in need of treatment. The cachexia is associated with, in other words a complication of, a primary disease, condition or disorder. Primary diseases, conditions and disorders include, but are not limited to, cancer, AIDS, liver cirrhosis, diabetes mellitus, chronic renal failure, chronic obstructive pulmonary disease, chronic cardiac failure, immune system diseases (e.g., rheumatoid arthritis and systemic lupus erythematosus), tuberculosis, cystic fibrosis, gastrointestinal disorders (e.g., irritable bowel syndrome and inflammatory bowel disease), Parkinson's disease, anorexia nervosa, dementia, major depression, an aged condition and sarcopenia.
• US6624154B1
  申请人：——

  公开号：US6624154B1

  公开（公告）日：2003-09-23